购物车
您的购物车当前为空
别名 LY-9818, LY9818, LY-519818, LY519818, LY 9818, LY 519818
Naveglitazar (LY 519818, LY 9818) is a peroxisome proliferator-activated receptor (PPAR) modulator, which has entered phase II clinical trials for the treatment of type 2 diabetes.

Naveglitazar (LY 519818, LY 9818) is a peroxisome proliferator-activated receptor (PPAR) modulator, which has entered phase II clinical trials for the treatment of type 2 diabetes.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 22,100 | 6-8周 | |
| 50 mg | ¥ 29,100 | 6-8周 | |
| 100 mg | ¥ 36,800 | 6-8周 |
| 产品描述 | Naveglitazar (LY 519818, LY 9818) is a peroxisome proliferator-activated receptor (PPAR) modulator, which has entered phase II clinical trials for the treatment of type 2 diabetes. |
| 别名 | LY-9818, LY9818, LY-519818, LY519818, LY 9818, LY 519818 |
| 分子量 | 422.47 |
| 分子式 | C25H26O6 |
| CAS No. | 476436-68-7 |
| Smiles | O(C1=CC=C(OCCCOC2=CC=C(C[C@@H](C(O)=O)OC)C=C2)C=C1)C3=CC=CC=C3 |
| 密度 | no data available |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
对于不同动物的给药剂量换算,您也可以参考 更多